Stockscreener 앱 받기
8.56
1.30%
0.11
시간 외 거래:
8.56
전일 마감가:
$8.45
열려 있는:
$8.6
하루 거래량:
348.03K
Relative Volume:
0.35
시가총액:
$192.97M
수익:
$146.07M
순이익/손실:
$-196.04M
주가수익비율:
-0.515
EPS:
-16.621
순현금흐름:
$-75.37M
1주 성능:
+18.07%
1개월 성능:
+9.04%
6개월 성능:
+43.87%
1년 성능:
+100.94%
1일 변동 폭
$8.40
$8.81
1주일 범위
$7.19
$8.87
52주 변동 폭
$3.6503
$10.99
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
명칭
Karyopharm Therapeutics Inc
전화
617-658-0600
주소
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
8.56 | 190.49M | 146.07M | -196.04M | -75.37M | -16.62 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | Rodman & Renshaw | Buy |
| 2026-02-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-10-13 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | 재개 | H.C. Wainwright | Buy |
| 2023-01-19 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-08-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | 개시 | Morgan Stanley | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-07-23 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-05 | 재확인 | Robert W. Baird | Outperform |
| 2019-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-02-28 | 재확인 | BofA/Merrill | Underperform |
| 2019-02-27 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | 개시 | B. Riley FBR | Buy |
| 2018-11-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2018-05-24 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-04-02 | 재개 | Leerink Partners | Outperform |
| 2017-11-15 | 재개 | H.C. Wainwright | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2016-09-08 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-08-18 | 개시 | H.C. Wainwright | Buy |
| 2016-06-28 | 개시 | Robert W. Baird | Outperform |
모두보기
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
Karyopharm to seek label expansion for Xpovio in myelofibrosis after late-stage trial win - MSN
KPTI stock slumps pre-market even as Karyopharm’s myelofibrosis treatment meets primary endpoint — retail doubtful about FDA approval - MSN
Karyopharm Therapeutics (KPTI) price target decreased by 22.08% to 12.24 - MSN
Karyopharm Therapeutics jumps 18%, raises $30M privately - MSN
Karyopharm Therapeutics (KPTI) affiliated managers report 1.9%–2.3% stakes - Stock Titan
[ARS] Karyopharm Therapeutics Inc. SEC Filing - Stock Titan
Karyopharm (KPTI) seeks approval for director slate and larger equity plans - Stock Titan
Gains Report: Can Karyopharm Therapeutics Inc disrupt its industry2026 Investor Takeaways & Daily Profit Maximizing Tips - baoquankhu1.vn
KPTI Receives Reiterated "Buy" Rating from HC Wainwright & Co. | KPTI Stock News - GuruFocus
Portfolio Update: Will Karyopharm Therapeutics Inc stock benefit from M A2026 Stock Rankings & Safe Entry Point Identification - baoquankhu1.vn
Quarterly Earnings: How sensitive is Karyopharm Therapeutics Inc to inflationPortfolio Gains Report & AI Enhanced Trading Alerts - baoquankhu1.vn
RBC Capital Adjusts Karyopharm Therapeutics PT to $16 From $23, Maintains Outperform Rating - Moomoo
Dip Buying: Is Karyopharm Therapeutics Inc attractive for institutional investors2026 Update & Growth Oriented Trading Recommendations - baoquankhu1.vn
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
RA Capital (NASDAQ: KPTI) and partners report 9.99% stake in Karyopharm - Stock Titan
Commodore Group discloses 1.95M KPTI stake; 19,618,032 shares O/S - Stock Titan
Karyopharm Therapeutics Inc. R (25K0.DU) insider ownership and holdings - Yahoo Finance Australia
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Up 20.9% in March - MarketBeat
Will Karyopharm Therapeutics Inc benefit from green energy policiesInsider Buying & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Piper Sandler Lowers Price Target for Karyopharm Therapeutics (K - gurufocus.com
Piper Sandler Reaffirms "Overweight" Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
Karyopharm stock price target cut to $8 by Piper Sandler on trial results - ca.investing.com
Karyopharm Therapeutics Inc (KPTI) Stock Price, Quote, News & History - benzinga.com
Karyopharm Strengthens Liquidity With New Equity Financing - tipranks.com
Karyopharm Therapeutics raises $30 million in private placement with RA Capital - Investing.com Australia
Karyopharm Therapeutics raises $30 million in private placement with RA Capital By Investing.com - Investing.com South Africa
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar? - Yahoo Finance
HC Wainwright Has Optimistic Outlook of KPTI Q1 Earnings - MarketBeat
Karyopharm Therapeutics raises ~$30M in private placement, adds ~$19.8M via ATM - TradingView
Karyopharm (NASDAQ: KPTI) completes $30M private placement and ATM sale - Stock Titan
Karyopharm: Putting The Phase 3 Trial In Context (NASDAQ:KPTI) - Seeking Alpha
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data - Yahoo Finance
KPTI: Baird Lowers Price Target, Maintains Outperform Rating | K - GuruFocus
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $15.00 at Robert W. Baird - MarketBeat
HC Wainwright Lowers Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $8.00 - MarketBeat
H.C. Wainwright cuts Karyopharm stock price target on trial results By Investing.com - Investing.com Canada
HC Wainwright & Co. Lowers Price Target on Karyopharm Therapeuti - GuruFocus
Karyopharm raises $30M in private placement with RA Capital By Investing.com - Investing.com Australia
Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark - Sahm
Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in MyelofibrosisSlideshow (NASDAQ:KPTI) 2026-03-25 - Seeking Alpha
Karyopharm myeloma drug yields mixed data in myelofibrosis trial - BioPharma Dive
Karyopharm’s myelofibrosis trial meets one of two primary goals By Investing.com - Investing.com India
KPTI Shares Fall Following Varied Results from Phase III Myelofibrosis Combination Study - Bitget
Karyopharm Therapeutics falls as pivotal trial hits spleen goal but misses symptom mark - msn.com
Leerink cuts Karyopharm stock price target on mixed trial data By Investing.com - ca.investing.com
Karyopharm Therapeutics Inc (KPTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):